<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00305669</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000455649</org_study_id>
    <secondary_id>UCSF-04558</secondary_id>
    <secondary_id>UCSF-H40568-25161-02B</secondary_id>
    <nct_id>NCT00305669</nct_id>
  </id_info>
  <brief_title>GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer</brief_title>
  <official_title>A Pilot Study of Two Dose Schedules of Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) as Neo-Adjuvant Therapy in Patients With Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Colony-stimulating factors, such as GM-CSF, may help the body build an effective&#xD;
      immune response to kill tumor cells. Giving GM-CSF before surgery may be an effective&#xD;
      treatment for localized prostate cancer.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well giving GM-CSF before surgery works in&#xD;
      treating patients with localized prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety and tolerability of daily neoadjuvant sargramostim (GM-CSF) in&#xD;
           patients with localized prostate cancer undergoing radical prostatectomy.&#xD;
&#xD;
        -  Determine whether tissue-specific antiprostate cancer immunity is induced by the&#xD;
           administration of neoadjuvant GM-CSF in patients with localized prostate cancer prior to&#xD;
           radical prostatectomy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Estimate the baseline antitumor immune response in patients treated with 2 different&#xD;
           dose schedules of GM-CSF.&#xD;
&#xD;
        -  Determine the magnitude of the difference in immune response between 2 dose schedules of&#xD;
           GM-CSF.&#xD;
&#xD;
        -  Determine the clinical effects, including prostate-specific antigen (PSA) decline,&#xD;
           surgical outcome, surgical complications, and histologic appearance of surgical&#xD;
           specimen, of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a pilot study. Patients are stratified according to sargramostim (GM-CSF)&#xD;
      dose.&#xD;
&#xD;
      Patients receive 1 of 2 dose levels of GM-CSF subcutaneously on days 1-14 or 1-21. Treatment&#xD;
      continues in the absence of unacceptable toxicity. Within 3 days after the last dose of&#xD;
      GM-CSF, patients undergo radical prostatectomy.&#xD;
&#xD;
      Blood is collected at baseline, day 28 of each course, and at the 4-week follow-up visit and&#xD;
      is examined for activated T-cells. Tissue is collected during surgery and assessed for&#xD;
      biomarkers and cytokines.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 28 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the safety and tolerability of daily neoadjuvant sargramostim (GM-CSF) in patients with localized prostate cancer undergoing radical prostatectomy.</measure>
    <time_frame>up to 6 weeks following surgery</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>GM-CSF before surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GM-CSF dose prior to surgery- Cohort 1-GM-CSF 250mcg/m2 for 2 weeks Cohort 2-GM-CSF 250mcg/m2 for 3 weeks Cohort 3-GM-CSF 250mcg/m2 for 4 weeks Cohort 4-GM-CSF 125mcg/m2 for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <arm_group_label>GM-CSF before surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <arm_group_label>GM-CSF before surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunological diagnostic method</intervention_name>
    <arm_group_label>GM-CSF before surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>GM-CSF before surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <arm_group_label>GM-CSF before surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <arm_group_label>GM-CSF before surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  No neuroendocrine or small cell features&#xD;
&#xD;
          -  No evidence of metastatic disease&#xD;
&#xD;
          -  Planning radical prostatectomy at least 2 months from now&#xD;
&#xD;
          -  Testosterone level normal&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status (PS) 0-1 or Karnofsky PS 70-100%&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL&#xD;
&#xD;
          -  AST and ALT ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  PT and PTT normal&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  No history of allergic reaction to compounds of similar chemical or biologic&#xD;
             composition to sargramostim (GM-CSF)&#xD;
&#xD;
          -  No ongoing or active bacterial, viral, or fungal infection&#xD;
&#xD;
          -  DLCO &gt; 50% if patient has a history of clinically significant obstructive airway&#xD;
             disease&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No other active malignancy, defined as cancer for which therapy has been completed and&#xD;
             patient is now considered &lt; 30% risk of relapse, except nonmelanoma skin cancer&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No underlying medical condition that, in the opinion of the principal investigator,&#xD;
             may make the administration of GM-CSF hazardous or obscure the interpretation of&#xD;
             adverse events&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
          -  No prior radiotherapy, immunotherapy, chemotherapy, or other investigational therapy&#xD;
             for this cancer&#xD;
&#xD;
          -  No prior hormonal therapy including any of the following:&#xD;
&#xD;
               -  Luteinizing-hormone releasing hormone (LHRH) agonists&#xD;
&#xD;
               -  LHRH antagonists&#xD;
&#xD;
               -  Antiandrogens, including any of the following:&#xD;
&#xD;
                    -  Bilcalutamide&#xD;
&#xD;
                    -  Flutamide&#xD;
&#xD;
                    -  Nilutamide&#xD;
&#xD;
               -  5-alpha-reductase inhibitors&#xD;
&#xD;
               -  PC-SPES or other PC-x product&#xD;
&#xD;
               -  Estrogen-containing nutriceuticals&#xD;
&#xD;
          -  No concurrent chemotherapy or radiotherapy&#xD;
&#xD;
          -  No concurrent systemic steroid therapy&#xD;
&#xD;
               -  Concurrent inhaled or topical steroids allowed&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
          -  No other concurrent investigational agent&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapies&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Fong, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>March 21, 2006</study_first_submitted>
  <study_first_submitted_qc>March 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2006</study_first_posted>
  <last_update_submitted>June 24, 2014</last_update_submitted>
  <last_update_submitted_qc>June 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

